COMPANY PROFILE

CinDome Pharma

Explore full profile

Innovative treatment advancing care for chronic gastroparesis

Cincinnati, United StatesFounded 2019Biotech & Life Sciences

Valuation $100–250M Last recorded · 2024

Total funding $50–100M Disclosed equity funding

Unlock exact values

About CinDome Pharma

CinDome Pharma, a CinRx portfolio company, is dedicated to developing deudomperidone (CIN-102) as a new treatment option for chronic gastroparesis, a condition characterized by delayed gastric emptying, leading to symptoms like abdominal discomfort, nausea, and vomiting. With 12-16 million people in the U.S. affected by this debilitating condition and limited long-term treatment options, CinDome Pharma aims to address this unmet need. Deudomperidone is a novel formulation of a dopamine D2/D3 antagonist designed to maintain the efficacy of traditional treatments while improving safety. Its prokinetic and antiemetic effects provide symptom relief without anticholinergic activity, offering hope for better management of gastroparesis.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2019
Headquarters: Cincinnati, United States
Open positions: None listed
Dealroom signal: 20.0/100
Industry: Health
Sub-industry: Pharmaceutical, BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Biotech and Pharma, DT and LS, science-based
Business model: Manufacturing
Client focus: b2b
Links: Website

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

2 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SERIES BOther financing	May 2024	$40M	$160M	Perceptive Advisors · CinRx Pharma	↗
SERIES BOther financing	Apr 2023	$19M	$76M	CinRx Pharma	↗

Showing the latest 2 of 2 recorded eventsBook a demo for the full funding history →

Growth signals

CinDome Pharma website traffic

Latest recorded traffic for CinDome Pharma is 480 monthly website visits, down 11.1% over the last three months.

Latest monthly visits480 3-month web change-11.1%

Monthly website visitsMay 2024–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
RTR1 TherapeuticsPharmaceutical therapies targeting neurological, metabolic and infectious conditions	Temecula, United States	Operational	16	$78M	$310M
AVAviadoBioPrecision gene therapies for neurodegenerative disorders	London, United Kingdom	Operational
TTTay TherapeuticsBiotech platform enhancing patient-specific medicines through advanced discovery and development expertise	Dundee, United Kingdom	Operational
SISPES Pharmaceuticals Inc.The company focuses on the research and development of improved specialty injectable products 505(b)(2)and complex generic drugs	United States	Operational
PRPrecirixCamelid-derived radiopharmaceuticals for targeted cancer therapy	Jette, Belgium	Operational
MTMestag TherapeuticsDeveloping antibody therapeutics targeting fibroblast-immune interactions	Little Chesterford, United Kingdom	Operational
EHEdifice HealthOffers inflammatory health monitoring tests to help manage chronic inflammation and improve overall health and longevity	San Mateo, United States	Operational
CTCV6 TherapeuticsCombination therapies enhancing cornerstone cancer and inflammatory treatments	Belfast, United Kingdom	Operational